Recently, a novel plaque-targeted nano-GLP-1RA (GlpNP) drug has been designed, synthesized and injected at very low doses twice a week for six weeks in ApoE-/- mice to allow decoupling of systemic effects in effort to understand the impact of direct plaque delivery on atherosclerosis. The gene discussed is APOE; the disease is atherosclerosis.